Dead cells don't form tumors

HIF-dependent cytotoxins

Patrick D. Sutphin, Denise A. Chan, Amato J. Giaccia

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Elimination or reduction of tumor burden is the primary goal of cancer therapy. Strategies to achieve this goal with the fewest adverse effects to the patient are an area of intense investigation. Elevated protein levels of hypoxia-inducible factor (HIF) are commonly found in solid tumors, while rarely found in healthy tissue. Numerous studies have suggested that HIF activity is essential for the development of solid tumors. Thus, inhibition of HIF represents an attractive therapeutic target for eradicating tumors. The search for small molecules that target and inhibit HIF activity is currently underway. We propose an alternate approach: to directly target and kill HIF-activated tumor cells. This approach is advantageous in that cells with activated HIF will be eliminated directly. Specific elimination of HIF-activated cells represents a potential mechanism for inhibiting tumor growth, with the potential advantage of sparing the patient of the normal tissue toxicity associated with current treatment options.

Original languageEnglish (US)
Pages (from-to)160-163
Number of pages4
JournalCell Cycle
Volume3
Issue number2
StatePublished - Feb 2004

Fingerprint

Cytotoxins
Tumors
Neoplasms
Tissue
Toxicity
Tumor Hypoxia
Hypoxia
Tumor Burden
Cells
Therapeutics
Molecules
Growth
Proteins

Keywords

  • Cytotoxins
  • Drug discovery
  • HIF-1α
  • Hypoxia
  • Targeted-therapy
  • VHL

ASJC Scopus subject areas

  • Cell Biology
  • Biochemistry
  • Molecular Biology

Cite this

Sutphin, P. D., Chan, D. A., & Giaccia, A. J. (2004). Dead cells don't form tumors: HIF-dependent cytotoxins. Cell Cycle, 3(2), 160-163.

Dead cells don't form tumors : HIF-dependent cytotoxins. / Sutphin, Patrick D.; Chan, Denise A.; Giaccia, Amato J.

In: Cell Cycle, Vol. 3, No. 2, 02.2004, p. 160-163.

Research output: Contribution to journalArticle

Sutphin, PD, Chan, DA & Giaccia, AJ 2004, 'Dead cells don't form tumors: HIF-dependent cytotoxins', Cell Cycle, vol. 3, no. 2, pp. 160-163.
Sutphin, Patrick D. ; Chan, Denise A. ; Giaccia, Amato J. / Dead cells don't form tumors : HIF-dependent cytotoxins. In: Cell Cycle. 2004 ; Vol. 3, No. 2. pp. 160-163.
@article{d9158855126c403192e992e543330ef3,
title = "Dead cells don't form tumors: HIF-dependent cytotoxins",
abstract = "Elimination or reduction of tumor burden is the primary goal of cancer therapy. Strategies to achieve this goal with the fewest adverse effects to the patient are an area of intense investigation. Elevated protein levels of hypoxia-inducible factor (HIF) are commonly found in solid tumors, while rarely found in healthy tissue. Numerous studies have suggested that HIF activity is essential for the development of solid tumors. Thus, inhibition of HIF represents an attractive therapeutic target for eradicating tumors. The search for small molecules that target and inhibit HIF activity is currently underway. We propose an alternate approach: to directly target and kill HIF-activated tumor cells. This approach is advantageous in that cells with activated HIF will be eliminated directly. Specific elimination of HIF-activated cells represents a potential mechanism for inhibiting tumor growth, with the potential advantage of sparing the patient of the normal tissue toxicity associated with current treatment options.",
keywords = "Cytotoxins, Drug discovery, HIF-1α, Hypoxia, Targeted-therapy, VHL",
author = "Sutphin, {Patrick D.} and Chan, {Denise A.} and Giaccia, {Amato J.}",
year = "2004",
month = "2",
language = "English (US)",
volume = "3",
pages = "160--163",
journal = "Cell Cycle",
issn = "1538-4101",
publisher = "Landes Bioscience",
number = "2",

}

TY - JOUR

T1 - Dead cells don't form tumors

T2 - HIF-dependent cytotoxins

AU - Sutphin, Patrick D.

AU - Chan, Denise A.

AU - Giaccia, Amato J.

PY - 2004/2

Y1 - 2004/2

N2 - Elimination or reduction of tumor burden is the primary goal of cancer therapy. Strategies to achieve this goal with the fewest adverse effects to the patient are an area of intense investigation. Elevated protein levels of hypoxia-inducible factor (HIF) are commonly found in solid tumors, while rarely found in healthy tissue. Numerous studies have suggested that HIF activity is essential for the development of solid tumors. Thus, inhibition of HIF represents an attractive therapeutic target for eradicating tumors. The search for small molecules that target and inhibit HIF activity is currently underway. We propose an alternate approach: to directly target and kill HIF-activated tumor cells. This approach is advantageous in that cells with activated HIF will be eliminated directly. Specific elimination of HIF-activated cells represents a potential mechanism for inhibiting tumor growth, with the potential advantage of sparing the patient of the normal tissue toxicity associated with current treatment options.

AB - Elimination or reduction of tumor burden is the primary goal of cancer therapy. Strategies to achieve this goal with the fewest adverse effects to the patient are an area of intense investigation. Elevated protein levels of hypoxia-inducible factor (HIF) are commonly found in solid tumors, while rarely found in healthy tissue. Numerous studies have suggested that HIF activity is essential for the development of solid tumors. Thus, inhibition of HIF represents an attractive therapeutic target for eradicating tumors. The search for small molecules that target and inhibit HIF activity is currently underway. We propose an alternate approach: to directly target and kill HIF-activated tumor cells. This approach is advantageous in that cells with activated HIF will be eliminated directly. Specific elimination of HIF-activated cells represents a potential mechanism for inhibiting tumor growth, with the potential advantage of sparing the patient of the normal tissue toxicity associated with current treatment options.

KW - Cytotoxins

KW - Drug discovery

KW - HIF-1α

KW - Hypoxia

KW - Targeted-therapy

KW - VHL

UR - http://www.scopus.com/inward/record.url?scp=1642532874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642532874&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 160

EP - 163

JO - Cell Cycle

JF - Cell Cycle

SN - 1538-4101

IS - 2

ER -